CD8A and cancer: As VentX has been shown to modulate phagocytosis,22 to elucidate the mechanisms of VentX-TAM in promoting efficacy of PD-1 antibody against NSCLC, we hypothesized that VentX promotes NSCLC-TAM phagocytosis of NSCLC tumor cells, which in turn, promotes CD8 T cell activation in a cancer-specific manner.